Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma

about

Current status and perspectives of patient-derived xenograft models in cancer research.Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation.The PI3K Pathway in Human Disease.Quantitative self-assembly prediction yields targeted nanomedicines.

P2860

Q33667686-3E14462A-9D3E-4139-90F0-89DC7149CB08 Q33776949-2163F2A4-778A-43FA-B107-A00060121884 Q46546002-E72A6DC0-43C0-45C5-8E87-456E2D43A5B0 Q48102709-5B9685A8-CC39-4E27-AFCC-308F3E8F59EC

P2860

Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma

Item

http://www.wikidata.org/entity/Q41838545

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Tumour-specific PI3K inhibitio ...... d neck squamous cell carcinoma

@en

type

Item

label

Tumour-specific PI3K inhibitio ...... d neck squamous cell carcinoma

@en

prefLabel

Tumour-specific PI3K inhibitio ...... d neck squamous cell carcinoma

@en

P1476

Tumour-specific PI3K inhibitio ...... d neck squamous cell carcinoma

@en

P2093

Aviram Mizrachi

http://www.w3.org/2001/XMLSchema#string

Janki Shah

http://www.w3.org/2001/XMLSchema#string

Joanne Soong

http://www.w3.org/2001/XMLSchema#string

John H Healey

http://www.w3.org/2001/XMLSchema#string

John L Humm

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

Maurizio Scaltriti

http://www.w3.org/2001/XMLSchema#string

Samuel Brook

http://www.w3.org/2001/XMLSchema#string

Simon N Powell

http://www.w3.org/2001/XMLSchema#string

Vinagolu K Rajasekhar

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin signalling and the regulation of glucose and lipid metabolism

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Cancer statistics, 2016

Cancer nanotechnology: opportunities and challenges

P2888

ncomms14292

P304

14292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS14292

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel A. Heller

Adriana Haimovitz-Friedman

P577

2017-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28194032

http://www.w3.org/2001/XMLSchema#string

P921

nanoparticle

P932

5316830

http://www.w3.org/2001/XMLSchema#string

Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma

about

P2860

P2860

Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932